Vertex Pharmaceuticals Inc.

VRTX

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions. Next phase2 readout (Tezacaftor/Ivacaftor): Jun 2017. Short interest: 1.9% of float.

BiotechnologyCEO: Reshma KewalramaniIPO: 1991Website ↗

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Catalysts

Phase 2NegativeQ4 2008CethrinSpinal Cord InjuryNCT00500812

Primary: The primary goal of this study is to determine the safety and tolerability of Cethrin when administered in conjunction with fibrin sealant to the dura mater of the spinal cord. (Prestudy, 24-72 hrs, 6 weeks, 3, 6 & 12 months)Enrollment:48/48Sites: 8NON_RANDOMIZED, TREATMENT

Phase 2PositiveQ1 2010TelaprevirHepatitis CNCT00535847

Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Treatment (24 weeks after the completion of treatment (up to Week 72))Enrollment:117/117Sites: 62NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2010telaprevirHepatitis CNCT00758043

Primary: Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24) (24 weeks after the last planned dose of study treatment)Enrollment:540/540Sites: 82RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2014Lumacaftor Plus Ivacaftor CombinationCystic Fibrosis, Homozygous for the F508del CFTR MutationNCT01807923

Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline, Week 16 and 24)Enrollment:559/559Sites: 89RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2014VX-135Chronic Hepatitis C, CHC, HCVNCT01842451

Primary: The safety and tolerability as assessed by adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), echocardiograms, and laboratory assessments (Up to 64 weeks)Enrollment:23/23Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ2 2017Tezacaftor/IvacaftorCystic FibrosisNCT02508207

Phase 3ApprovedQ3 2017LUM/IVACystic FibrosisNCT02797132

Phase 2PositiveQ4 2017VX-150Acute PainNCT03206749

Primary: Time-weighted Sum of the Pain Intensity Difference (SPID) Between VX-150 Versus Placebo as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 24 Hours After the First Dose (0 to 24 hours after the first dose)Enrollment:243/243Sites: 4RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ4 2018VX-210Cervical Spinal Cord InjuryNCT02669849

Phase 2PositiveQ4 2020LUM/IVACystic FibrosisNCT03625466

Phase 3ApprovedQ4 2020TEZ/IVACystic FibrosisNCT03537651

Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Day 1 up to Week 100)Enrollment:130/130Sites: 55NA, TREATMENT

Phase 2NegativeQ4 2020VX-814Alpha 1-Antitrypsin DeficiencyNCT04167345

Primary: Change in Plasma Functional Alpha-1 Antitrypsin (AAT) Levels (From Baseline at Day 28)Enrollment:48/48Sites: 28RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2021ELX/TEZ/IVACystic FibrosisNCT04353817

Phase 3Q4 2021LUMCystic FibrosisNCT03601637

Phase 2Q4 2021VX-147Glomerulosclerosis, Focal SegmentalNCT04340362

Phase 3PositiveQ2 2022ELX/TEZ/IVACystic FibrosisNCT04537793

Primary: Part A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites (From Day 1 through Day 15)Enrollment:83/83Sites: 22NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2023ELX/TEZ/IVACystic FibrosisNCT04545515

Primary: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Baseline up to Week 100)Enrollment:120/120Sites: 34NA, TREATMENT

Phase 3PositiveQ3 2023ELX/TEZ/IVACystic FibrosisNCT05274269

Phase 2Q3 2024ALPN-101Systemic Lupus ErythematosusNCT04835441

Phase 2Q2 2025VX-993Acute PainNCT06619847

Phase 2Q2 2026VX-522 mRNA therapyCystic FibrosisNCT05668741

Phase 2Q2 2026VX-993Diabetic Peripheral Neuropathic PainNCT06619860

Phase 2Q2 2026VX-264Type 1 DiabetesNCT05791201

Phase 3Q2 2026CTX001Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea IntoleranceNCT05329649

Phase 3Q2 2026CTX001Beta-Thalassemia, Thalassemia, Genetic Diseases, InbornNCT05356195

Phase 3Q3 2026Biological/VaccineType 1 Diabetes, Kidney TransplantNCT06832410

Phase 3Q4 2026VX-121/TEZ/D-IVACystic FibrosisNCT05444257

Phase 3Q1 2027SuzetrigineDiabetic Peripheral Neuropathic PainNCT06696443

Phase 2Q1 2027VX-670Myotonic Dystrophy Type 1 (DM1)NCT06185764

Phase 3Q2 2027ELX/TEZ/IVACystic FibrosisNCT05331183

Phase 3Q2 2027SuzetrigineDiabetic Peripheral Neuropathic PainNCT07231419

Phase 3Q2 2027SuzetrigineDiabetic Peripheral Neuropathic PainNCT06628908

Phase 3Q2 2027CTX001Beta-Thalassemia, Thalassemia, Hematologic DiseasesNCT05477563

Phase 3Q2 2027VX-880Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe HypoglycemiaNCT04786262

Phase 2Q3 2027VX-407Autosomal Dominant Polycystic Kidney Disease (ADPKD)NCT07161037

Phase 3Q3 2027ELX/TEZ/IVACystic FibrosisNCT06460506

Phase 3Q1 2028PovetaciceptImmunoglobulin A NephropathyNCT06564142

Phase 3Q2 2028VX-147Proteinuric Kidney DiseaseNCT05312879

Phase 3Q4 2028PovetaciceptPrimary Membranous NephropathyNCT07204275

Phase 2Q1 2029VX-670Myotonic Dystrophy Type 1 (DM1)NCT06926621

Phase 2Q1 2029PovetaciceptMyasthenia Gravis, GeneralizedNCT07501702

Phase 3Q3 2029VNZ/TEZ/D-IVACystic FibrosisNCT05844449

Phase 3Q2 2030VX-121/TEZ/D-IVACystic FibrosisNCT05422222

Phase 3Q3 2039CTX001Beta-Thalassemia, Thalassemia, Sickle Cell DiseaseNCT04208529

Recent News & Research

PubMed

Once-daily hypertonic saline inhalation and airway clearance techniques in children with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor: a prospective multicentre study.

# Investment Summary: VRTX CF Triple Therapy Study This prospective study examines whether children with CF receiving Vertex's blockbuster triple therapy (Trikafta) can safely reduce airway clearance burden through hypertonic saline monotherapy, suggesting potential for simplified treatment regimens that could improve adherence and quality of life. The findings are clinically meaningful if they demonstrate that enhanced CFTR function from the triple therapy may reduce dependency on intensive airway clearance protocols, which could expand the commercial appeal of Trikafta in pediatric populations and strengthen competitive positioning. However, the study's relevance to VRTX's revenue trajectory depends on whether simplified protocols translate into broader uptake, reduced treatment discontinuations, or expanded label claims—outcomes that warrant monitoring as CF management guidelines evolve.

Aug 22, 2026

PubMed

Persistence of static lung hyperinflation in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.

# Investment Summary: VRTX Elexacaftor-Tezacaftor-Ivacaftor Study This study demonstrates that while the triple CFTR modulator combination (Trikafta) significantly improves lung function metrics in CF patients, static hyperinflation—a marker of residual airway obstruction and disease—persists despite treatment. The finding suggests the drug may have reached a functional plateau in reversing structural lung damage, potentially limiting additional clinical benefit gains and raising questions about long-term disease progression endpoints in this patient population. **Investor Implication:** The result indicates Trikafta's clinical ceiling on pulmonary outcomes, which could affect peak sales expectations, payer reimbursement arguments based on comprehensive disease modification, and the commercial narrative around curative potential—relevant as VRTX considers next-generation modulator candidates and faces patent expiration considerations.

Aug 18, 2026

PubMed

Suzetrigine for Refractory Pain in Guillain-Barré Syndrome.

# Investment Summary: Suzetrigine in Guillain-Barré Syndrome **Clinical Finding:** This case report documents suzetrigine's potential efficacy in managing refractory pain associated with Guillain-Barré Syndrome (GBS), a rare autoimmune neuropathy where pain management remains inadequately addressed by standard therapies. **Investment Implications:** While encouraging, this represents early evidence from a single case study rather than controlled trial data; GBS-associated pain is a niche indication with limited patient population, though it could support label expansion for suzetrigine if larger studies validate efficacy. The finding is more relevant to Vertex's broader pain franchise positioning than near-term revenue drivers, given suzetrigine's current focus on diabetic peripheral neuropathy and other chronic pain conditions with larger addressable markets.

Aug 18, 2026

PubMed

Positioning suzetrigine in acute pain: does spontaneous pain hold the key?

# Vertex Pharmaceuticals (VRTX) - Suzetrigine Research Summary **Clinical/Commercial Significance:** This research examines suzetrigine's positioning in acute pain treatment, with particular focus on spontaneous pain as a potential key efficacy marker—a finding that could define the drug's competitive positioning against standard analgesics and inform its label claims in a competitive acute pain market. Spontaneous pain endpoints may be more clinically relevant than traditional evoked pain measurements, which could strengthen suzetrigine's clinical evidence package for FDA approval and subsequent market differentiation. This mechanistic insight is material for assessing suzetrigine's commercial potential given the large but saturated acute pain market where differentiation on clinically meaningful endpoints drives adoption and pricing power. **For Investors:** The study's focus on spontaneous pain positioning could clarify whether suzetrigine has a sustainable competitive advantage in acute pain or faces commoditization risk

Aug 1, 2026

PubMed

Suzetrigine, a novel nonopioid analgesic for acute pain.

# Investment Summary: Suzetrigine (VX-548) Suzetrigine represents Vertex's clinical-stage sodium channel blocker targeting acute pain management, positioning the company to compete in the large acute pain market traditionally dominated by opioids and NSAIDs. The nonopioid mechanism addresses regulatory and commercial demand for pain alternatives with potentially lower abuse liability and fewer GI/cardiovascular side effects, though market adoption depends on demonstrating efficacy parity with existing standards and navigating reimbursement for a new mechanism class. Success would provide VRTX meaningful revenue diversification beyond its CF/genetics franchise, but faces competition from other nonopioid analgesics in development and established acute pain treatments.

Aug 1, 2026

Vertex Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research